Quince Therapeutics Inc (QNCX)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Dirk Thye
Employees:
60
601 GATEWAY BOULEVARD, SUITE 1250, SOUTH SAN FRANCISCO, CA, 94080
415-910-5717

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor.

Data derived from most recent annual or quarterly report
Market Cap 55.141 Million Shares Outstanding36.277 Million Avg 30-day Volume 101.799 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-1.16
Price to Revenue0.0 Debt to Equity0.0 EBITDA-44.705 Million
Price to Book Value0.6201 Operating Margin0.0 Enterprise Value-34.744 Million
Current Ratio29.692 EPS Growth0.609 Quick Ratio28.958
1 Yr BETA 1.1372 52-week High/Low 3.35 / 0.54 Profit Margin0.0
Operating Cash Flow Growth51.82 Altman Z-Score5.841 Free Cash Flow to Firm -34.02 Million
View SEC Filings from QNCX instead.

View recent insider trading info

Quince Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding QNCX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding QNCX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-05-26 by MCLOUGHLIN MARGARET
  • 4: filed on 2023-05-26 by LAMOND DAVID
  • 4: filed on 2023-05-26 by BRAY JUNE
  • 4: filed on 2023-03-06 by MONOHON TED
  • 4: filed on 2023-02-02 by THYE DIRK
  • 4: filed on 2023-02-02 by SMITH KAREN L.
  • 4: filed on 2023-02-02 by MONOHON TED
  • 4: filed on 2023-02-02 by HANNAH BRENDAN
  • 4: filed on 2022-12-07 by MONOHON TED
  • 4: filed on 2022-09-08 by MONOHON TED

    • Events (8k)

  • 8-K: filed on 2023-05-25:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2023-04-05:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-28:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2023-03-03:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2023-01-27:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-12-16:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K: filed on 2022-09-30:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-08-01:
    Item 2.02: Results of Operations and Financial Condition
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-22:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-06-10:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    RYAN UNA S

    • Director
    		 0 2023-05-24 2

    SENNER CHRISTOPHER J.

    • Director
    		 0 2023-05-24 2

    LAMOND DAVID

    • Director
    		 0 2023-05-24 2

    MCLOUGHLIN MARGARET

    • Director
    		 0 2023-05-24 2

    BRAY JUNE

    • Director
    		 0 2023-05-24 3

    MONOHON TED CHIEF ACCOUNTING OFFICER & VP

    • Officer
    		 27,440 2023-03-06 5

    THYE DIRK CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 0 2023-02-01 1

    SMITH KAREN L. CHIEF MEDICAL OFFICER

    • Officer
    		 0 2023-02-01 1

    HANNAH BRENDAN CHIEF BUSINESS OFFICER

    • Officer
    		 0 2023-02-01 1

    MCDOWELL CARYN GORDON CHIEF LEGAL & ADM. OFFICER

    • Officer
    		 122,500 2022-06-06 0

    HOLSINGER LESLIE EVP, PRECLINICAL DEVELOPMENT

    • Officer
    		 148,080 2022-06-06 0

    LOW PHILIP S

    • Director
    		 0 2022-05-19 0

    SABBAGH MARWAN

    • Director
    		 0 2022-03-14 0

    LOWE CHRISTOPHER P. INTERIM CEO, COO & CFO

    • Officer
    		 265,000 2022-03-03 0

    DETKE MICHAEL J. CHIEF MEDICAL OFFICER

    • Officer
    		 140,000 2022-03-03 0

    LYNCH CASEY CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 440,000 2022-01-03 0

    DOMINY STEPHEN S. CHIEF SCIENTIFIC OFFICER

    • Officer
    • Director
    		 125,000 2022-01-03 0

    EPIQ CAPITAL GROUP, LLC

    BOEDING CHAD

    • FORMER 10% OWNERCEO OF FORMER 10% OWNER
    		 No longer subject to file 2020-12-31 0

    YOUNG KEVIN

    • Director
    		 0 2020-06-08 0

    GAFRIC KRISTEN SVP, LEGAL & ADMINISTRATION

    • Officer
    		 0 2020-02-06 0

    PFIZER INC

    PFIZER VENTURES (US) LLC

    PFIZER STRATEGIC INVESTMENT HOLDINGS LLC

    • 10% Owner
    		 3,249,973 2019-05-13 0

    CHIESI FARMACEUTICI SPA

    • 10% Owner
    		 No longer subject to file 2014-02-03 0

    WALSH CHRISTOPHER T PHD

    • Director
    		 15,000 2007-05-02 0

    DUGAN RICHARD W

    • Director
    • LEAD INDEPENDENT DIRECTOR
    		 15,000 2007-05-02 0

    GEORGE JEAN

    • Director
    		 15,000 2007-05-02 0

    ZEIGER ROBERT H

    • Director
    		 15,000 2007-05-02 0

    ZWERLING M CORY

    • Director
    		 7,500 2007-05-02 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    BRAY JUNE - Director

    		2023-05-26 17:45:03 -0400 2023-05-24 A 27,000 a 27,000 direct

    LAMOND DAVID - Director

    		2023-05-26 17:47:13 -0400 2023-05-24 A 27,000 a 27,000 direct

    MCLOUGHLIN MARGARET - Director

    		2023-05-26 17:49:15 -0400 2023-05-24 A 27,000 a 27,000 direct

    RYAN UNA S - Director

    		2023-05-26 17:50:54 -0400 2023-05-24 A 27,000 a 27,000 direct

    SENNER CHRISTOPHER J. - Director

    		2023-05-26 17:53:52 -0400 2023-05-24 A 27,000 a 27,000 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    QUINCE THERAPEUTICS INC QNCX 2023-06-07 22:15:04 UTC -25.4728 30.5428 500000
    QUINCE THERAPEUTICS INC QNCX 2023-06-07 21:45:05 UTC -25.4728 30.5428 500000
    QUINCE THERAPEUTICS INC QNCX 2023-06-07 21:15:04 UTC -25.377 30.447 500000
    QUINCE THERAPEUTICS INC QNCX 2023-06-07 20:45:04 UTC -25.377 30.447 500000
    QUINCE THERAPEUTICS INC QNCX 2023-06-07 20:15:06 UTC -25.377 30.447 500000
    QUINCE THERAPEUTICS INC QNCX 2023-06-07 19:45:04 UTC -25.377 30.447 500000
    QUINCE THERAPEUTICS INC QNCX 2023-06-07 19:15:04 UTC -25.377 30.447 500000
    QUINCE THERAPEUTICS INC QNCX 2023-06-07 18:45:04 UTC -25.377 30.447 500000
    QUINCE THERAPEUTICS INC QNCX 2023-06-07 18:15:03 UTC -25.377 30.447 500000
    QUINCE THERAPEUTICS INC QNCX 2023-06-07 17:45:05 UTC -25.377 30.447 500000
    QUINCE THERAPEUTICS INC QNCX 2023-06-07 17:15:04 UTC -25.377 30.447 500000
    QUINCE THERAPEUTICS INC QNCX 2023-06-07 16:45:03 UTC -25.377 30.447 500000
    QUINCE THERAPEUTICS INC QNCX 2023-06-07 16:15:04 UTC -25.377 30.447 500000
    QUINCE THERAPEUTICS INC QNCX 2023-06-07 15:45:04 UTC -25.377 30.447 500000
    QUINCE THERAPEUTICS INC QNCX 2023-06-07 15:15:04 UTC -25.377 30.447 500000
    QUINCE THERAPEUTICS INC QNCX 2023-06-07 14:45:04 UTC -25.377 30.447 500000
    QUINCE THERAPEUTICS INC QNCX 2023-06-07 14:15:03 UTC -25.377 30.447 500000
    QUINCE THERAPEUTICS INC QNCX 2023-06-07 13:45:03 UTC -25.142 30.212 500000
    QUINCE THERAPEUTICS INC QNCX 2023-06-07 13:15:04 UTC -25.142 30.212 550000
    QUINCE THERAPEUTICS INC QNCX 2023-06-07 12:45:04 UTC -25.142 30.212 500000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments